Enviomycin

Identification

Name
Enviomycin
Accession Number
DB08993
Type
Small Molecule
Groups
Experimental
Description

Cyclic basic peptide related to viomycin. It is isolated from an induced mutant of Streptomyces griseoverticillatus var. tuberacticus and acts as an antitubercular agent with less ototoxicity than tuberactinomycin.

Structure
Thumb
Synonyms
  • Enviomicina
  • Enviomycin
  • Enviomycine
  • Enviomycinum
  • Tuberactinomycin N
Product Ingredients
IngredientUNIICASInChI Key
Enviomycin Sulfate67846BXW6553760-33-1Not applicable
International/Other Brands
Tuberactin (Asahi Kasei Pharma)
Categories
UNII
XU299C23A2
CAS number
33103-22-9
Weight
Average: 685.69
Monoisotopic: 685.325584661
Chemical Formula
C25H43N13O10
InChI Key
HPWIIERXAFODPP-GHBBWTPBSA-N
InChI
InChI=1S/C25H43N13O10/c26-3-1-16(41)10(27)5-17(42)33-12-6-31-23(47)18(11-2-4-30-24(28)37-11)38-20(44)13(7-32-25(29)48)34-21(45)14(8-39)36-22(46)15(9-40)35-19(12)43/h7,10-12,14-16,18,39-41H,1-6,8-9,26-27H2,(H,31,47)(H,33,42)(H,34,45)(H,35,43)(H,36,46)(H,38,44)(H3,28,30,37)(H3,29,32,48)/b13-7-/t10-,11-,12+,14+,15+,16-,18+/m1/s1
IUPAC Name
(3R,4R)-3,6-diamino-4-hydroxy-N-[(3S,6Z,9S,12S,15S)-2,5,8,11,14-pentahydroxy-6-{[(C-hydroxycarbonimidoyl)amino]methylidene}-9,12-bis(hydroxymethyl)-3-[(4R)-2-imino-1,3-diazinan-4-yl]-1,4,7,10,13-pentaazacyclohexadeca-1,4,7,10,13-pentaen-15-yl]hexanimidic acid
SMILES
[H]\C(NC(O)=N)=C1\N=C(O)[C@]([H])(CO)N=C(O)[C@]([H])(CO)N=C(O)[C@]([H])(CN=C(O)[C@@]([H])(N=C1O)[C@@]1([H])CCNC(=N)N1)N=C(O)C[C@@]([H])(N)[C@]([H])(O)CCN

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Mycobacterium tuberculosis
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Enviomycin is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Enviomycin is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Enviomycin is combined with 4-hydroxycoumarin.
AcenocoumarolThe risk or severity of bleeding can be increased when Enviomycin is combined with Acenocoumarol.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Enviomycin.
Anthrax immune globulin humanThe therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Enviomycin.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Enviomycin.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Enviomycin.
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Enviomycin.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Enviomycin.
Food Interactions
Not Available

References

Synthesis Reference

U.S. Patent 3,892,732.

General References
Not Available
External Links
KEGG Drug
D07897
PubChem Compound
20055267
PubChem Substance
310264954
ChemSpider
16736480
ChEMBL
CHEMBL2146142
Drugs.com
Drugs.com Drug Page
Wikipedia
Enviomycin

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.155 mg/mLALOGPS
logP-1.4ALOGPS
logP-9.6ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)2.5ChemAxon
pKa (Strongest Basic)11.74ChemAxon
Physiological Charge3ChemAxon
Hydrogen Acceptor Count23ChemAxon
Hydrogen Donor Count17ChemAxon
Polar Surface Area412.29 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity186.22 m3·mol-1ChemAxon
Polarizability65.21 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Cyclic peptides
Alternative Parents
Diazinanes / 1,3-aminoalcohols / Cyclic carboximidic acids / Secondary alcohols / 1,2-aminoalcohols / Guanidines / Isoureas / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Carboximidamides
show 6 more
Substituents
Cyclic alpha peptide / 1,3-diazinane / 1,3-aminoalcohol / Cyclic carboximidic acid / 1,2-aminoalcohol / Guanidine / Isourea / Secondary alcohol / Carboximidic acid / Carboximidic acid derivative
show 19 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 16, 2014 09:39 / Updated on November 02, 2018 08:46